Research programme: analgesic/famotidine fixed combinations - Horizon

Drug Profile

Research programme: analgesic/famotidine fixed combinations - Horizon

Alternative Names: Aspirin/famotidine; HZN-602; HZT-602; HZT-703; Immediate-release naproxen/high-dose famotidine (HZT-602); Naproxen/famotidine

Latest Information Update: 26 Apr 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Horizon Therapeutics
  • Developer Horizon Pharma USA
  • Class
  • Mechanism of Action Cyclooxygenase inhibitors; Histamine H2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Pain

Most Recent Events

  • 23 Mar 2012 Discontinued - Preclinical for Pain in USA (PO)
  • 01 Apr 2010 Horizon Therapeutics has merged with Nitec Pharma forming Horizon Pharma
  • 23 Jul 2007 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top